Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blockbuster drugs in its pipeline. To name a few, Sotatercept - is in late stage clinical trials...
